A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Postherpetic Neuralgia
NCT ID: NCT00424372
Last Updated: 2021-08-27
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
126 participants
INTERVENTIONAL
2007-01-12
2008-08-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia
NCT00394901
To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Postherpetic Neuralgia.
NCT00150436
A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin In Patients With Fibromyalgia
NCT00830128
Pregabalin for Treatment of Patients With Postherpetic Neuralgia (PHN)
NCT01455428
Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Chronic Neuropathic Pain.
NCT00141362
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
pregabalin
pregabalin
Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pregabalin
Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must be able to understand and cooperate with study procedures and have signed a written informed consent prior to entering the study.
Exclusion Criteria
* Patients exhibiting treatment non-compliance in the preceding study (A0081120)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gunma Pain Clinic Hospital
Maebashi, Gunma, Japan
Takasaki Pain Clinic
Takasaki, Gunma, Japan
Asahikawa Pain Clinic Hospital
Asahikawa, Hokkaido, Japan
Kamui Pain Clinic
Asahikawa, Hokkaido, Japan
Sapporo Asabu Clinic
Sapporo, Hokkaido, Japan
Higashi Sapporo Hospital
Sapporo, Hokkaido, Japan
Seimei Clinic
Akashi, Hyōgo, Japan
Uchida Pain Relief Clinic
Amagasaki, Hyōgo, Japan
National Hospital Organization Himeji Medical Center
Himeji, Hyōgo, Japan
National Hospital Organization Nagoya Medical Center
Nagoya, Aichi-ken, Japan
Kobayashi Clinic
Urayasu, Chiba, Japan
Okabe Hospital
Kasuya-gun, Fukuoka, Japan
National Hospital Organization Kobe Medical Center
Kobe, Hyōgo, Japan
Nakamura Clinic
Kobe, Hyōgo, Japan
National Hospital Organization Sagamihara National Hospital
Sagamihara, Kanagawa, Japan
Suzuki Pain Clinic
Yokohama, Kanagawa, Japan
Hajiri Pain Clinic
Yokohama, Kanagawa, Japan
National Hospital Organization Yokohama Medical Center
Yokohama, Kanagawa, Japan
Sendai Pain Clinic
Sendai, Miyagi, Japan
Nakamura Hospital
Beppu, Ohita, Japan
Kawaguchi Kogyo General Hospital
Kawaguchi, Saitama, Japan
Kinoshita Clinic
Tokorozawa, Saitama, Japan
Tokyo Women's Medical University Center East
Arakawa-ku, Tokyo, Japan
Juntendo University Hospital
Bunkyo-ku, Tokyo, Japan
Mitaka Pain Clinic
Mitaka, Tokyo, Japan
Toriumi Pain Clinic
Nakano-ku, Tokyo, Japan
Kanto Medical NTT East Corporation
Shinagawa-ku, Tokyo, Japan
Naganuma Pain Clinic
Shinagawa-ku, Tokyo, Japan
Tokyo Women's Medical University Hospital
Shinjuku-ku, Tokyo, Japan
Mukai Clinic
Fukuoka, , Japan
KM Pain Clinic
Fukuoka, , Japan
Otsuki Sleep Clinic
Fukushima, , Japan
Hasumi Pain Clinic
Saitama, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A0081121
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.